NCT02667236View on ClinicalTrials.gov

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Seborrheic Keratosis
Interventions
DRUG

A-101 Solution

Active Drug

OTHER

Vehicle Solution

Placebo

Trial Locations (1)

19355

Aclaris Therapeutics, Inc., Malvern

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY